Note: This variant has not been sufficiently evaluated by a GET-Evidence editor.
To be considered sufficiently evaluated a variant must have both "variant evidence" and "clinical importance" scores filled in.
Please help improve GET-Evidence by evaluating evidence for this variant!
You are viewing an old version of this page that was saved on May 17, 2010 at 6:14pm by PharmGKB Importing Robot.
Increased plasma AUC with repaglinide.
Insufficiently evaluated pharmacogenetic
(The "insufficiently evaluated" qualifier is assigned automatically based on the above evidence and importance scores.)
Summary of published research, and additional commentary
Added in this revision:
Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C: identification
of multiple allelic variants associated with altered transport activity among
European- and African-Americans. J Biol Chem. 2001 Sep 21;276(38):35669-75. Epub
2001 Jul 26. PubMed PMID: 11477075.
Zaïr ZM, Eloranta JJ, Stieger B, Kullak-Ublick GA. Pharmacogenetics of OATP
(SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine,
liver and kidney. Pharmacogenomics. 2008 May;9(5):597-624. Review. PubMed PMID:
SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S,
Matsuda F, Gut I, Lathrop M, Collins R. SLCO1B1 variants and statin-induced
myopathy--a genomewide study. N Engl J Med. 2008 Aug 21;359(8):789-99. Epub 2008
Jul 23. PubMed PMID: 18650507.
Pasanen MK, Miettinen TA, Gylling H, Neuvonen PJ, Niemi M. Polymorphism of the
hepatic influx transporter organic anion transporting polypeptide 1B1 is
associated with increased cholesterol synthesis rate. Pharmacogenet Genomics.
2008 Oct;18(10):921-6. PubMed PMID: 18794729.